Drug watchdog: tracking a Biologic's Real-World impact on painful skin and joint diseases
NCT ID NCT07243782
Summary
This study is monitoring the safety and real-world effectiveness of an existing drug, Cosentyx, in patients with three chronic inflammatory conditions: hidradenitis suppurativa (painful skin lumps), pediatric plaque psoriasis, and juvenile arthritis. It will observe about 76 patients in Korea who are already prescribed the drug as part of their normal care. The main goal is to collect information on side effects and see how well the drug works for symptom control in everyday practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06973, South Korea
Conditions
Explore the condition pages connected to this study.